DE202015105351U1 - Diätetische Zusammensetzung - Google Patents

Diätetische Zusammensetzung Download PDF

Info

Publication number
DE202015105351U1
DE202015105351U1 DE202015105351.7U DE202015105351U DE202015105351U1 DE 202015105351 U1 DE202015105351 U1 DE 202015105351U1 DE 202015105351 U DE202015105351 U DE 202015105351U DE 202015105351 U1 DE202015105351 U1 DE 202015105351U1
Authority
DE
Germany
Prior art keywords
pharmaceutical
acid
composition according
uridine
mthf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE202015105351.7U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apotheke Am Schlossplatz Inh Mario Ganster E K
Apotheke Am Schlossplatz Inh Mario Ganster EK
Original Assignee
Apotheke Am Schlossplatz Inh Mario Ganster E K
Apotheke Am Schlossplatz Inh Mario Ganster EK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotheke Am Schlossplatz Inh Mario Ganster E K, Apotheke Am Schlossplatz Inh Mario Ganster EK filed Critical Apotheke Am Schlossplatz Inh Mario Ganster E K
Priority to DE202015105351.7U priority Critical patent/DE202015105351U1/de
Priority to FR1560195A priority patent/FR3042120A3/fr
Publication of DE202015105351U1 publication Critical patent/DE202015105351U1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
DE202015105351.7U 2015-10-09 2015-10-09 Diätetische Zusammensetzung Expired - Lifetime DE202015105351U1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE202015105351.7U DE202015105351U1 (de) 2015-10-09 2015-10-09 Diätetische Zusammensetzung
FR1560195A FR3042120A3 (enExample) 2015-10-09 2015-10-26

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE202015105351.7U DE202015105351U1 (de) 2015-10-09 2015-10-09 Diätetische Zusammensetzung

Publications (1)

Publication Number Publication Date
DE202015105351U1 true DE202015105351U1 (de) 2016-01-07

Family

ID=55235360

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202015105351.7U Expired - Lifetime DE202015105351U1 (de) 2015-10-09 2015-10-09 Diätetische Zusammensetzung

Country Status (2)

Country Link
DE (1) DE202015105351U1 (enExample)
FR (1) FR3042120A3 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672745A (zh) * 2018-08-29 2021-04-16 阿普罗福尔公司 叶酸类化合物制剂
CN116103161A (zh) * 2022-11-16 2023-05-12 三峡大学 一种产泽兰素的植物内生真菌及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119405662A (zh) * 2024-11-01 2025-02-11 华中科技大学同济医学院附属同济医院 5-甲基四氢叶酸在调控效应cd8+t细胞中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003837A1 (en) 1987-10-28 1989-05-05 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
EP1390378A1 (en) 2001-04-30 2004-02-25 Trommsdorff GmbH & Co. KG Arzneimittel Pharmaceutically active uridine esters
WO2007089703A2 (en) 2006-01-30 2007-08-09 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
EP1044975B1 (de) 1999-04-15 2009-12-09 Merck Eprova AG Stabiles kristallines Salz der 5-Methyl-(6S)-tetrahydrofolsäure
WO2013066167A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013125020A1 (ja) 2012-02-23 2013-08-29 関東化学株式会社 脱水素用触媒、該触媒を用いたカルボニル化合物および水素の製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003837A1 (en) 1987-10-28 1989-05-05 Pro-Neuron, Inc. Acylated uridine and cytidine and uses thereof
EP1044975B1 (de) 1999-04-15 2009-12-09 Merck Eprova AG Stabiles kristallines Salz der 5-Methyl-(6S)-tetrahydrofolsäure
EP1390378A1 (en) 2001-04-30 2004-02-25 Trommsdorff GmbH & Co. KG Arzneimittel Pharmaceutically active uridine esters
WO2007089703A2 (en) 2006-01-30 2007-08-09 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
WO2013066167A1 (en) 2011-10-31 2013-05-10 N.V. Nutricia Method for improving executive function
WO2013125020A1 (ja) 2012-02-23 2013-08-29 関東化学株式会社 脱水素用触媒、該触媒を用いたカルボニル化合物および水素の製造方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Becroft DM et al., 1969, J. Pedriatr 75: 885-891
Monticone et al., 1966, Minerva Med. 57: 4348-4352
Morris & Gotor (J. Organic Chemistry, 1993; 58: 653-660)
Roberts et al., 1974, Epilepsia 15: 497-500

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672745A (zh) * 2018-08-29 2021-04-16 阿普罗福尔公司 叶酸类化合物制剂
CN116103161A (zh) * 2022-11-16 2023-05-12 三峡大学 一种产泽兰素的植物内生真菌及其应用

Also Published As

Publication number Publication date
FR3042120A3 (enExample) 2017-04-14

Similar Documents

Publication Publication Date Title
DE69906345T2 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
DE60127970T2 (de) Zusammensetzung, welche ein antifolate und ein methylmalonsäuresenkendes mittel enthält
DE69618158T2 (de) Pharmazeutische Zusammensetzung enthaltend ein Alkanoyl-L-Carnitin in Kombination mit einer polyungesättigten Fettsäure der Omega-3-Serie zur Verhütung und Behandlung von Störungen des Fettstoffwechsels
DE202015105351U1 (de) Diätetische Zusammensetzung
DE10054278A1 (de) Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
EP1641460A2 (de) Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat
DE10326822A1 (de) Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
US7230131B2 (en) Carnitine-magnesium hydroxycitrate
DE102007053369A1 (de) Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
KR102224087B1 (ko) 지효성 고체 경구용 조성물
JP4458761B2 (ja) 瀉下用製剤
AU2014349782A1 (en) Slow-release solid oral compositions
DE102004038155A1 (de) Physiologisch verträgliche Zusammensetzung enthaltend alpha-Liponsäure, Kreatin und ein Phospholipid
EP3277273B1 (en) A composition for the treatment of neuropathies and/or neuropathic pain
DE202011109556U1 (de) Eisenhaltige Vitaminzusammensetzung
EP1835917A1 (de) Mittel, enthaltend folsäure, vitamin b6 und vitamin b12, und dessen verwendung
DE69112376T3 (de) Verbesserte Therapiemethode.
KR101324425B1 (ko) 증가된 비스포스포네이트의 생체이용률을 가지는 경구투여 약제
CH648208A5 (de) Pharmazeutisches mittel zur herabsetzung der endogenen oxalatbildung.
AT396427B (de) Pharmazeutische verwendung eines oxipurinolsalzes
EP3305327B1 (de) Lipidsenker
WO2003043622A1 (de) Substituierte bicyclo[3.3.1]nonan-2,4,9-trione als pharmazeutische wirkstoffe
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie
TH2101006855A (th) รูปแบบยาของแข็งทางเภสัชกรรมหรือเภสัชโภชนศาสตร์ที่มีหลายชั้นซึ่งประกอบรวมด้วยอนุพันธุ์ไพริมิดีนและ/หรือพิวรีน และวิตามินบี, การเตรียมและการใช้งานสารนั้น
AU2023312625A1 (en) Uridine triacetate amorphous formulation and uses thereof

Legal Events

Date Code Title Description
R207 Utility model specification
R156 Lapse of ip right after 3 years